home / stock / srzn / srzn quote
Last: | $10.9899 |
---|---|
Change Percent: | 4.4% |
Open: | $9.77 |
Close: | $10.9899 |
High: | $10.9899 |
Low: | $9.55 |
Volume: | 4,138 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$10.9899 | $9.77 | $10.9899 | $10.9899 | $9.55 | 4,138 | 07-03-2024 |
$10.22 | $10.36 | $10.22 | $10.69 | $10.22 | 2,087 | 07-02-2024 |
$10.7 | $11 | $10.7 | $11 | $9.64 | 1,215 | 07-01-2024 |
$10.95 | $9.55 | $10.95 | $11 | $9.47 | 7,693 | 06-28-2024 |
$9.94 | $9.43 | $9.94 | $10 | $9.43 | 6,972 | 06-27-2024 |
$10.56 | $10.56 | $10.56 | $10.56 | $10.56 | 1,445 | 06-26-2024 |
$9.95 | $10.18 | $9.95 | $10.18 | $9.18 | 3,746 | 06-25-2024 |
$10.2 | $9.69 | $10.2 | $10.2 | $9.69 | 4,416 | 06-24-2024 |
$9.69 | $9.88 | $9.69 | $10.34 | $9.3 | 38,681 | 06-21-2024 |
$10.04 | $10.4 | $10.04 | $10.42 | $10.04 | 1,361 | 06-20-2024 |
$10.25 | $10.57 | $10.25 | $11 | $10.25 | 2,391 | 06-19-2024 |
$10.25 | $10.57 | $10.25 | $11 | $10.25 | 2,391 | 06-18-2024 |
$10.9999 | $10.1354 | $10.9999 | $11.13 | $9.9821 | 5,987 | 06-17-2024 |
$11.19 | $11.015 | $11.19 | $11.3317 | $11.015 | 1,534 | 06-14-2024 |
$11.27 | $11.38 | $11.27 | $11.38 | $10.91 | 7,314 | 06-13-2024 |
$11.43 | $10.8 | $11.43 | $11.43 | $10.8 | 3,193 | 06-12-2024 |
$11.38 | $11.1 | $11.38 | $11.4299 | $11.1 | 3,279 | 06-11-2024 |
$11.2 | $11.1 | $11.2 | $11.25 | $10.4935 | 11,805 | 06-10-2024 |
$11.09 | $10.12 | $11.09 | $11.0999 | $10.12 | 5,298 | 06-07-2024 |
$10.425 | $10.7 | $10.425 | $10.7 | $10 | 6,031 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Targeted protein degradation (TPD * ) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are unique TPD technologies Results demonstrated that the two new ASGR-targeted SWEETS bispecific a...
SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Phase 1...
SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1 Anticipate potential proof-of-concept data available in the first half of 2025 SOUTH SAN FRANSCISO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen...